---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042421"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T09:59:07.405616+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q2 net loss narrows to $1.5M; FDA clears Ph1/Part B of ReSPECT-LM

## Summary
- Q2 2023 net loss of $1.5M ($0.59/share) vs $5.3M ($3.56/share) in Q2 2022.
- Cash balance $10.9M at June 30, 2023, down from $18.1M at Dec 31, 2022; expects $1.9M CPRIT grant soon.
- FDA approval to advance ReSPECT-LM trial to Phase 1/Part B for leptomeningeal metastases.
- Total operating expenses fell 35% YoY to $3.3M due to lower R&D spend after initial cGMP work.
- New VP of Clinical Operations Pius Maliakal appointed; expanded Piramal Pharma supply collaboration.

## SEC filing metadata
- accession: 0000950170-23-042421
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017023042421/0000950170-23-042421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017023042421/pstv-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042421
- JSON: https://secwatch.observer/filing/0000950170-23-042421.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042421.txt

## Key facts
- Earnings Releases
  PLUS THERAPEUTICS, INC. reported the second quarter ended June 30, 2023 results: net income $(1.5) million, EPS $(0.59) per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $(1.5) million
  - EPS: $(0.59) per share
  - Result: reported results
  source text: Net loss for the second quarter of 2023 was $(1.5) million, or $(0.59) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023042421/0000950170-23-042421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.